The Endocannabinoid System, Cannabinoids, and Pain

Abstract

The endocannabinoid system is involved in a host of homeostatic and physiologic functions, including modulation of pain and inflammation. The specific roles of currently identified endocannabinoids that act as ligands at endogenous cannabinoid receptors within the central nervous system (primarily but not exclusively CB1 receptors) and in the periphery (primarily but not exclusively CB2 receptors) are only partially elucidated, but they do exert an influence on nociception. Exogenous plant-based cannabinoids (phytocannabinoids) and chemically related compounds, like the terpenes, commonly found in many foods, have been found to exert significant analgesic effects in various chronic pain conditions. Currently, the use of Δ9-tetrahydrocannabinol is limited by its psychoactive effects and predominant delivery route (smoking), as well as regulatory or legal constraints. However, other phytocannabinoids in combination, especially cannabidiol and β-caryophyllene, delivered by the oral route appear to be promising candidates for the treatment of chronic pain due to their high safety and low adverse effects profiles. This review will provide the reader with the foundational basic and clinical science linking the endocannabinoid system and the phytocannabinoids with their potentially therapeutic role in the management of chronic pain.

Unpredictable chronic stress decreases inhibitory avoidance learning in Tuebingen Long-Fin zebrafish (Danio rerio Hamilton): stronger effects in the resting phase than in the active phase

“…Further studies focusing on chronic stress and CNR1 in zebrafish seem warranted. Studies on mammals have also shown that CB1 is associated with pain and pain perception, where activation of CB1 reduces pain sensitivity (Fine and Rosenfeld, 2013;Guindon and Hohmann, 2009;Wilson and Nicoll, 2002). Higher levels of CNR1 could contribute to poorer inhibitory avoidance learning as the paradigm is based on a potentially noxious stimulus (i.e.…”

Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity

“…Trends toward improvements with THC:CBD oromucosal spray in patients with 1 or 2 failed prior therapy attempts were broadly similar to those in the ITT population and, occasionally, were even more pronounced, such as the significant improvement in the SF-36 domain of 'bodily pain' in patients in Group 1 which might be explained by the analgesic effect of THC:CBD [17][18][19] . The lack of statistical significance for this same quality of life measure in patients in Group 2 likely reflects the smaller sample size as the same trend was evident.…”

Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis

“…Cannabis has an inhibitory effect via augmentation of gamma-amino-butyric acid (GABA) pathways in the central nervous system (131–133). This produces motor neuron inhibition at spinal levels in mice.…”